JP2010502708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010502708A5 JP2010502708A5 JP2009527404A JP2009527404A JP2010502708A5 JP 2010502708 A5 JP2010502708 A5 JP 2010502708A5 JP 2009527404 A JP2009527404 A JP 2009527404A JP 2009527404 A JP2009527404 A JP 2009527404A JP 2010502708 A5 JP2010502708 A5 JP 2010502708A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- neuropathy
- item
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000124008 Mammalia Species 0.000 claims description 20
- 230000024203 complement activation Effects 0.000 claims description 19
- 201000001119 neuropathy Diseases 0.000 claims description 18
- 230000007823 neuropathy Effects 0.000 claims description 18
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 12
- 206010033799 Paralysis Diseases 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 8
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 7
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 7
- 206010003591 Ataxia Diseases 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 210000003141 lower extremity Anatomy 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 210000000715 neuromuscular junction Anatomy 0.000 claims description 6
- 206010065580 Lewis-Sumner syndrome Diseases 0.000 claims description 4
- 208000028389 Nerve injury Diseases 0.000 claims description 4
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims description 4
- 230000008764 nerve damage Effects 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 208000021090 palsy Diseases 0.000 claims description 4
- 230000004962 physiological condition Effects 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 102000004856 Lectins Human genes 0.000 claims description 2
- 108090001090 Lectins Proteins 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 108091030071 RNAI Proteins 0.000 claims description 2
- 206010070833 Respiratory muscle weakness Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000001977 ataxic effect Effects 0.000 claims description 2
- 210000003050 axon Anatomy 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000000133 brain stem Anatomy 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims description 2
- 229960002224 eculizumab Drugs 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 208000033699 familial Guillain-Barre syndrome Diseases 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000009368 gene silencing by RNA Effects 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 208000018904 loss of tendon reflex Diseases 0.000 claims description 2
- 208000013465 muscle pain Diseases 0.000 claims description 2
- 239000000816 peptidomimetic Substances 0.000 claims description 2
- 229950003203 pexelizumab Drugs 0.000 claims description 2
- 208000025156 pharyngeal-cervical-brachial variant of Guillain-Barre syndrome Diseases 0.000 claims description 2
- 230000003518 presynaptic effect Effects 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 230000011514 reflex Effects 0.000 claims description 2
- 238000007665 sagging Methods 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 208000037118 sensory ataxia Diseases 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 230000005062 synaptic transmission Effects 0.000 claims description 2
- 210000001364 upper extremity Anatomy 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84229606P | 2006-09-05 | 2006-09-05 | |
| US60/842,296 | 2006-09-05 | ||
| PCT/US2007/019416 WO2008030505A2 (en) | 2006-09-05 | 2007-09-05 | Methods and compositions for the treatment of antibody mediated neuropathies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014196133A Division JP2014240438A (ja) | 2006-09-05 | 2014-09-26 | 抗体媒介性ニューロパシーを処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010502708A JP2010502708A (ja) | 2010-01-28 |
| JP2010502708A5 true JP2010502708A5 (https=) | 2011-08-11 |
| JP5695317B2 JP5695317B2 (ja) | 2015-04-01 |
Family
ID=39157834
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009527404A Expired - Fee Related JP5695317B2 (ja) | 2006-09-05 | 2007-09-05 | 抗体媒介性ニューロパシーを処置するための方法および組成物 |
| JP2014196133A Pending JP2014240438A (ja) | 2006-09-05 | 2014-09-26 | 抗体媒介性ニューロパシーを処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014196133A Pending JP2014240438A (ja) | 2006-09-05 | 2014-09-26 | 抗体媒介性ニューロパシーを処置するための方法および組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9388235B2 (https=) |
| EP (4) | EP2380907B1 (https=) |
| JP (2) | JP5695317B2 (https=) |
| KR (1) | KR101503540B1 (https=) |
| AU (1) | AU2007293013B2 (https=) |
| BR (1) | BRPI0715869A2 (https=) |
| CA (1) | CA2662480C (https=) |
| DK (1) | DK2061810T3 (https=) |
| ES (2) | ES2616204T3 (https=) |
| IL (1) | IL197148A (https=) |
| MX (1) | MX2009002426A (https=) |
| NZ (1) | NZ575018A (https=) |
| PL (1) | PL2061810T3 (https=) |
| PT (1) | PT2061810E (https=) |
| SI (1) | SI2061810T1 (https=) |
| WO (1) | WO2008030505A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| AU2009307661B2 (en) * | 2008-10-21 | 2014-11-20 | Thomas M. Donndelinger | Methods and compositions for preventing artifacts in tissue samples |
| EP3511339B1 (en) | 2012-02-20 | 2025-04-09 | IPC Research, LLC | Polypeptides binding to human complement c5 |
| EP3722320A3 (en) | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| EP2997045A4 (en) * | 2013-05-15 | 2016-11-23 | Annexon Inc | ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF |
| DK3019240T3 (da) | 2013-07-09 | 2024-06-03 | Annexon Inc | Anti-komplementfaktor C1Q antistoffer og anvendelser deraf |
| US9994605B2 (en) | 2014-03-13 | 2018-06-12 | Universitaet Basel | Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein |
| SI3215527T1 (sl) | 2014-11-05 | 2025-04-30 | Annexon, Inc. | Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba |
| WO2016097865A1 (en) * | 2014-12-19 | 2016-06-23 | Regenesance B.V. | Antibodies that bind human c6 and uses thereof |
| CA2981321A1 (en) | 2015-04-06 | 2016-10-13 | True North Therapeutics, Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| CA2996073A1 (en) | 2015-09-16 | 2017-03-23 | Universitat Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
| EP3380518B1 (en) | 2015-11-24 | 2026-03-25 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| CN110300520B (zh) | 2016-10-12 | 2022-10-04 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| CA3274059A1 (en) | 2017-12-13 | 2026-03-02 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| EP3870221A1 (en) * | 2018-10-22 | 2021-09-01 | RA Pharmaceuticals, Inc. | Neurological disease treatment with zilucoplan |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| JP2022535411A (ja) | 2019-06-04 | 2022-08-08 | ラ ファーマシューティカルズ インコーポレイテッド | 補体阻害剤による炎症性疾患治療 |
| US12486322B2 (en) | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
| TW202404632A (zh) * | 2022-04-04 | 2024-02-01 | 瑞士商赫孚孟拉羅股份公司 | 用於藉由使用抗ｃ５抗體克羅伐單抗治療或預防格林－巴利症候群之劑量及投予方案 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US6121424A (en) | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5705732A (en) | 1989-06-12 | 1998-01-06 | Oklahoma Medical Research Foundation | Universal donor cells |
| US5135916A (en) | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU9149791A (en) | 1990-12-06 | 1992-07-08 | T Cell Sciences, Inc. | Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| DE69534347T2 (de) | 1994-01-31 | 2006-05-24 | Trustees Of Boston University, Boston | Bibliotheken aus Polyklonalen Antikörpern |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| DE69534701T2 (de) | 1994-09-23 | 2006-10-19 | Alexion Pharmaceuticals, Inc., Cheshire | Verfahren zur behandlung von entzündlichen gelenkerkrankungen |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| WO1999037149A1 (en) * | 1998-01-27 | 1999-07-29 | Brigham & Women's Hospital | Methods of treating cytotoxic damage |
| US6492403B1 (en) * | 1999-02-09 | 2002-12-10 | 3-Dimensional Pharmaceuticals, Inc. | Methods of treating C1s-mediated diseases and conditions and compositions thereof |
| EP2896631A1 (en) * | 2000-10-10 | 2015-07-22 | Genentech, Inc. | Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| ES2283594T5 (es) | 2001-08-17 | 2016-03-15 | Genentech, Inc. | Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| ITMI20021527A1 (it) * | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| US20040091490A1 (en) | 2002-08-28 | 2004-05-13 | Robert Johnson | Stable pH optimized formulation of a modified antibody |
| AU2004207003A1 (en) | 2003-01-30 | 2004-08-12 | Medimmune, Llc | Anti-integrin alphanubeta3 antibody formulations and uses thereof |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| US20050019326A1 (en) | 2003-06-16 | 2005-01-27 | The Brigham And Women's Hospital, Inc. | C1q complement inhibitors and methods of use thereof |
| US7482376B2 (en) * | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
| EP1739078A1 (de) * | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| JP5722524B2 (ja) | 2006-03-02 | 2015-05-20 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体活性を抑制することによる同種移植片の生存の延長 |
-
2007
- 2007-09-05 US US12/439,070 patent/US9388235B2/en active Active
- 2007-09-05 BR BRPI0715869-6A2A patent/BRPI0715869A2/pt not_active Application Discontinuation
- 2007-09-05 EP EP11005615.7A patent/EP2380907B1/en active Active
- 2007-09-05 AU AU2007293013A patent/AU2007293013B2/en active Active
- 2007-09-05 SI SI200731601T patent/SI2061810T1/sl unknown
- 2007-09-05 PL PL07837788T patent/PL2061810T3/pl unknown
- 2007-09-05 ES ES11005615.7T patent/ES2616204T3/es active Active
- 2007-09-05 DK DK07837788.4T patent/DK2061810T3/en active
- 2007-09-05 ES ES07837788T patent/ES2530428T3/es active Active
- 2007-09-05 WO PCT/US2007/019416 patent/WO2008030505A2/en not_active Ceased
- 2007-09-05 NZ NZ575018A patent/NZ575018A/en not_active IP Right Cessation
- 2007-09-05 PT PT78377884T patent/PT2061810E/pt unknown
- 2007-09-05 MX MX2009002426A patent/MX2009002426A/es active IP Right Grant
- 2007-09-05 CA CA2662480A patent/CA2662480C/en active Active
- 2007-09-05 KR KR1020097004369A patent/KR101503540B1/ko active Active
- 2007-09-05 EP EP16201244.7A patent/EP3199549A1/en not_active Withdrawn
- 2007-09-05 EP EP07837788.4A patent/EP2061810B1/en active Active
- 2007-09-05 JP JP2009527404A patent/JP5695317B2/ja not_active Expired - Fee Related
- 2007-09-05 EP EP14192554.5A patent/EP2913342A1/en not_active Withdrawn
-
2009
- 2009-02-19 IL IL197148A patent/IL197148A/en active IP Right Grant
-
2014
- 2014-09-26 JP JP2014196133A patent/JP2014240438A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010502708A5 (https=) | ||
| JP5695317B2 (ja) | 抗体媒介性ニューロパシーを処置するための方法および組成物 | |
| Gasser et al. | Targeting IgE in allergic disease | |
| JP5954916B1 (ja) | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| RU2008137764A (ru) | Способы предотвращения и лечения амилоидных заболеваний | |
| JP2019523295A5 (https=) | ||
| JP2021514973A5 (https=) | ||
| RU2016118769A (ru) | Способы лечения состояний, ассоциированных с masp-2-зависимой активацией комплемента | |
| US20240158483A1 (en) | Anti-c1s antibodies and uses thereof | |
| JP2020518638A5 (https=) | ||
| JP2023548005A (ja) | 抗トランスサイレチン抗体およびその使用方法 | |
| JP2022519293A5 (https=) | ||
| JP2023506779A5 (https=) | ||
| RU2016127196A (ru) | Способ лечения ран | |
| JP2023177377A (ja) | 多発性硬化症治療薬 | |
| WO2025238225A1 (en) | Methods of treating osteoarthritis and osteoarthritis pain with an anti complement c2 antagonistic antibody | |
| RU2024123507A (ru) | Способы лечения состояний, ассоциированных с masp-2-зависимой активацией комплемента | |
| HK1163703B (en) | Methods and compositions for the treatment of antibody mediated neuropathies | |
| HK1126793B (en) | Methods and compositions for the treatment of antibody mediated neuropathies | |
| HK1163703A (en) | Methods and compositions for the treatment of antibody mediated neuropathies | |
| NZ783304B2 (en) | Methods for inhibiting fibrosis in a subject in need thereof | |
| NZ783304A (en) | Methods for inhibiting fibrosis in a subject in need thereof |